REGN17372+Linvoseltamab

PreclinicalMonoclonal antibody

REGN17372+Linvoseltamab is one of 24 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Relapsed Refractory Multiple Myeloma (RRMM)Recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Relapsed Refractory Multiple Myeloma (RRMM)Preclinical

Recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Prolia

Amgen

Preclinical

5 2

Eliquis

Bristol-Myers Squibb

Preclinical

3 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 4

Adriamycin

GGynecologic Oncology Group

Preclinical

9 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Systemic Therapy

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

PreclinicalRecruiting

Relapsed Refractory Multiple Myeloma (RRMM)

NCT07455851

Clinical

Trials by Indication[1]

Relapsed Refractory Multiple Myeloma (RRMM)1 trial

A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT07455851·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for REGN17372+Linvoseltamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN17372+Linvoseltamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN17372+Linvoseltamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: Regeneron

REGN17372+Linvoseltamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Trials by Indication[1]

Relapsed Refractory Multiple Myeloma (RRMM)1 trial

References

Drug Info

Quick Facts

Related News